Immunome Inc. Insider Trading

IMNM

Last 12 months

Insiders bought $2.31M and sold $27.5M on the open market.

94% of the selling was scheduled in advance under 10b5-1 plans. Director Philip Wagenheim sold $1.34M on Mar 23, 16% of their stake, outside a plan.

Net open-market

−$25.2M

8 buys · 15 sales

Under a 10b5-1 plan

94%

of the value sold

Insiders who bought / sold

3 / 7

executives and directors

Last open-market buy

Jun 2026

Jun 5, 2026

Get an email when IMNM's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 11	Jack Higgins Chief Scientific Officer	Sold10b5-1 plan	13,200	$25.32	334K	18%	Form 4
Aug 10 – 12	Isaac Barchas Director	Sold10b5-1 plan 3 parts	83,464	$26.35 average	$2.2M	48%	Form 4
Aug 6 – 7	Isaac Barchas Director	Sold10b5-1 plan 2 parts	36,088	$26.06 average	940K	17%	Form 4
Aug 4	Kinney Horn Chief Business Officer	Sold10b5-1 plan	90,616	$25.09	$2.27M	100%	Form 4
Jul 7	Kinney Horn Chief Business Officer	Sold10b5-1 plan	1,092	$25.00	27K	100%	Form 4
Jul 6 – 7	Isaac Barchas Director	Sold10b5-1 plan 2 parts	100,000	$24.13 average	$2.41M	32%	Form 4
Jul 2	Robert Lechleider Chief Medical Officer	Sold10b5-1 plan 3 parts	55,000	$22.62 average	$1.24M	78%	Form 4
Jun 30 – Jul 2	Isaac Barchas Director	Sold10b5-1 plan 3 parts	201,050	$21.85 average	$4.39M	24%	Form 4
Jun 25	Robert Lechleider Chief Medical Officer	Sold10b5-1 plan 2 parts	55,000	$19.85 average	$1.09M	78%	Form 4
Jun 15	Max Rosett Chief Financial Officer	Sold10b5-1 plan	60,000	$18.23	$1.09M	53%	Form 4
Jun 5	Jean Jacques Bienaime Director	Bought 3 parts	10,500	$19.45 average	204K	32%	Form 4
Jun 5	Jean Jacques Bienaime Director	SoldNo plan 2 parts	10,500	$19.41 average	204K	19%	Form 4
May 15	Jean Jacques Bienaime Director	Bought	5,000	$20.70	104K	13%	Form 4
Apr 2	Max Rosett Chief Financial Officer	Sold10b5-1 plan 2 parts	65,000	$21.92 average	$1.42M	55%	Form 4
Apr 2	Jack Higgins Chief Scientific Officer	Sold10b5-1 plan	9,438	$21.64	204K	27%	Form 4
Mar 27	Clay B Siegall President and CEO	Bought	25,450	$19.67	501K	3.8%	Form 4
Mar 20 – 23	Philip Wagenheim Director	SoldNo plan 2 parts	65,000	$20.55 average	$1.34M	16%	Form 4
Mar 10 – 11	Jean Jacques Bienaime Director	Bought 2 parts	2,000	$21.84 average	44K	5.5%	Form 4
Dec 30, 2025	Clay B Siegall President and CEO	Bought	4,729	$21.15	100K	0.7%	Form 4
Dec 22, 2025	Isaac Barchas Director	Sold10b5-1 plan 2 parts	383,200	$21.74 average	$8.33M	8.4%	Form 4
Dec 19, 2025	Philip Tsai Chief Technical Officer	Bought	10,000	$20.49	205K	30%	Form 4
Dec 19, 2025	Clay B Siegall President and CEO	Bought	7,278	$20.48	149K	1.1%	Form 4
Dec 18, 2025	Clay B Siegall President and CEO	Bought	46,511	$21.50	1000K	5.8%	Form 4
Jun 3, 2025	Jean Jacques Bienaime Director	Bought	5,000	$9.38	47K	16%	Form 4
Mar 26, 2025	Clay B Siegall President and CEO	Bought	137,100	$7.29	999K	20%	Form 4
Mar 25, 2025	Jean Jacques Bienaime Director	Bought	7,800	$7.78	61K	33%	Form 4
Mar 24, 2025	Jean Jacques Bienaime Director	Bought	7,000	$8.21	57K	42%	Form 4
Mar 24, 2025	Philip Tsai Chief Technology Officer	Bought	12,300	$8.42	104K	59%	Form 4
Jan 31, 2025	Clay B Siegall President and CEO	Bought	150,000	$7.75	$1.16M	29%	Form 4
Nov 21, 2024 – Nov 22, 2024	Clay B Siegall President and CEO	Bought 2 parts	100,000	$9.62 average	962K	24%	Form 4
Nov 21, 2024	Robert Lechleider Chief Medical Officer	Bought	15,805	$9.48	150K	New	Form 4
Nov 21, 2024	Philip Tsai Chief Technology Officer	Bought	21,000	$9.43	198K	New	Form 4

Sep 1110b5-1 plan
Jack Higgins
Chief Scientific Officer · sold 13,200 at $25.32
334K
18% of stake
Aug 10 – 1210b5-1 plan
Isaac Barchas
Director · sold 83,464 at avg $26.35
$2.2M
48% of stake
Aug 6 – 710b5-1 plan
Isaac Barchas
Director · sold 36,088 at avg $26.06
940K
17% of stake
Aug 410b5-1 plan
Kinney Horn
Chief Business Officer · sold 90,616 at $25.09
$2.27M
100% of stake
Jul 710b5-1 plan
Kinney Horn
Chief Business Officer · sold 1,092 at $25.00
27K
100% of stake
Jul 6 – 710b5-1 plan
Isaac Barchas
Director · sold 100,000 at avg $24.13
$2.41M
32% of stake
Jul 210b5-1 plan
Robert Lechleider
Chief Medical Officer · sold 55,000 at avg $22.62
$1.24M
78% of stake
Jun 30 – Jul 210b5-1 plan
Isaac Barchas
Director · sold 201,050 at avg $21.85
$4.39M
24% of stake
Jun 2510b5-1 plan
Robert Lechleider
Chief Medical Officer · sold 55,000 at avg $19.85
$1.09M
78% of stake
Jun 1510b5-1 plan
Max Rosett
Chief Financial Officer · sold 60,000 at $18.23
$1.09M
53% of stake
Jun 5
Jean Jacques Bienaime
Director · bought 10,500 at avg $19.45
204K
32% of stake
Jun 5No plan
Jean Jacques Bienaime
Director · sold 10,500 at avg $19.41
204K
19% of stake
May 15
Jean Jacques Bienaime
Director · bought 5,000 at $20.70
104K
13% of stake
Apr 210b5-1 plan
Max Rosett
Chief Financial Officer · sold 65,000 at avg $21.92
$1.42M
55% of stake
Apr 210b5-1 plan
Jack Higgins
Chief Scientific Officer · sold 9,438 at $21.64
204K
27% of stake
Mar 27
Clay B Siegall
President and CEO · bought 25,450 at $19.67
501K
3.8% of stake
Mar 20 – 23No plan
Philip Wagenheim
Director · sold 65,000 at avg $20.55
$1.34M
16% of stake
Mar 10 – 11
Jean Jacques Bienaime
Director · bought 2,000 at avg $21.84
44K
5.5% of stake
Dec 30, 2025
Clay B Siegall
President and CEO · bought 4,729 at $21.15
100K
0.7% of stake
Dec 22, 202510b5-1 plan
Isaac Barchas
Director · sold 383,200 at avg $21.74
$8.33M
8.4% of stake
Dec 19, 2025
Philip Tsai
Chief Technical Officer · bought 10,000 at $20.49
205K
30% of stake
Dec 19, 2025
Clay B Siegall
President and CEO · bought 7,278 at $20.48
149K
1.1% of stake
Dec 18, 2025
Clay B Siegall
President and CEO · bought 46,511 at $21.50
1000K
5.8% of stake
Jun 3, 2025
Jean Jacques Bienaime
Director · bought 5,000 at $9.38
47K
16% of stake
Mar 26, 2025
Clay B Siegall
President and CEO · bought 137,100 at $7.29
999K
20% of stake
Mar 25, 2025
Jean Jacques Bienaime
Director · bought 7,800 at $7.78
61K
33% of stake
Mar 24, 2025
Jean Jacques Bienaime
Director · bought 7,000 at $8.21
57K
42% of stake
Mar 24, 2025
Philip Tsai
Chief Technology Officer · bought 12,300 at $8.42
104K
59% of stake
Jan 31, 2025
Clay B Siegall
President and CEO · bought 150,000 at $7.75
$1.16M
29% of stake
Nov 21, 2024 – Nov 22, 2024
Clay B Siegall
President and CEO · bought 100,000 at avg $9.62
962K
24% of stake
Nov 21, 2024
Robert Lechleider
Chief Medical Officer · bought 15,805 at $9.48
150K
New position
Nov 21, 2024
Philip Tsai
Chief Technology Officer · bought 21,000 at $9.43
198K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch IMNM, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with IMNM

CompareIntrinsic value

TNGXTango Therapeutics Inc.

$23.18+0.04%40

SYBXSynlogic Inc.

$1.00+0.00%20

AQSTAquestive Therapeutics Inc.

$3.80-2.06%10

NGNENeurogene Inc.

$27.58+3.41%10

MREOMereo BioPharma Group plc

$0.30+4.12%10

COYACoya Therapeutics Inc.

$3.08-0.96%10

PRLDPrelude Therapeutics Incorporated

$4.08+7.94%40

PLRXPliant Therapeutics Inc.

$0.85-1.07%10

Held by ETFs

IMNM is in 39 US ETFs. The largest of them, with IMNM's weight in each:

Spot a number that looks wrong? Check it in IMNM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IMNM

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.